Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Maxcyte Inc (NQ: MXCT )

3.550 +0.100 (+2.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Maxcyte Inc

< Previous 1 2 3 4 5 Next >
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer... 
From MaxCyte, Inc
Via GlobeNewswire
Recap: MaxCyte Q3 Earnings
Via Benzinga
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones index falling over 250 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Cell Engineering Company MaxCyte Shares Are Up Today
MaxCyte Inc (NASDAQ: MXCT) shares are trading higher by over 9% after the company disclosed strong preliminary Q4 and full-year  
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline
Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases. 
From MaxCyte, Inc; Lion TCR
Via GlobeNewswire
MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
From MaxCyte, Inc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines 
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte to Participate in Two Upcoming Investor Conferences
From MaxCyte, Inc
Via GlobeNewswire
Cell Engineering MaxCyte Faces Challenge, Analysts Express Concerns Over Near-Term Prospects Amid Revenue Decline
MaxCyte Inc (NASDAQ: MXCT) shares plummeted after the company released preliminary Q3 revenue of $7.8 million – 8.0 million, a Y/Y decrease of 25 -27%, due to continued reduced 
Via Benzinga
Crude Oil Down 2%; ConAgra Brands Earnings Top Views
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.12% to 33,088.44 while the NASDAQ fell 0.23% to... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent... 
Via Benzinga
Why Shares of MaxCyte Are Plummeting on Thursday
The biotech company reduced full-year guidance and expects so-so third-quarter revenue. 
Via The Motley Fool
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The... 
Via Benzinga
Topics Stocks
Exposures US Equities
BB Stock Alert: What to Know as BlackBerry Plans IPO for IoT Division
BlackBerry stock is a hot topic among BB shareholders today alongside news the company is considering an IPO for its IoT business. 
Via InvestorPlace
Topics Initial Public Offering
Exposures Securities Market
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Is MaxCyte (MXCT) Stock Down 21% Today?
MaxCyte stock is taking a beating on Thursday as investors in MXCT shares react to preliminary results for its third quarter of 2023. 
Via InvestorPlace
Why Orchard Therapeutics Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are rising and falling on Thursday as we check out all of the latest news worth knowing about this morning! 
Via InvestorPlace
MaxCyte, Rivian Automotive And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Conagra Brands, Constellation Brands And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
From MaxCyte, Inc
Via GlobeNewswire
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
From MaxCyte, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.